Ascelia Pharma AB (publ)
The answer first
Does Ascelia Pharma beat the market?
No, Ascelia Pharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 16% of Nordic stocks
- Quality69
- Value13
- Trend13
No. 144 of 195 in healthcare
Max for seven days
Follow Ascelia Pharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Ascelia Pharma
Your first answer is free, no account needed.
Do you own Ascelia Pharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Ascelia Pharma and a few more. Free, no card.
Super Stock+45.9%In short
- Ascelia Pharma has fallen 78.7% over the past year, including dividends.
- Overall, Ascelia Pharma ranks better than 16% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.1%. The price is 99.1% below its peak now.
What do analysts think of Ascelia Pharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 16% of Nordic stocks.
No. 144 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 86 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−68.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 126 of 197 in healthcareTypical in healthcare: 21Typical in the Nordics: 50
- P/BPrice divided by equity1.0
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 148 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−2.7%
- 6 months−80.1%
- 9 months−81.4%
- 12 months−78.7%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Ascelia Pharma
4 funds we follow own Ascelia Pharma. The share is how much of the fund the stock makes up.
- Sweden4
From the funds' latest known holdings.
About Ascelia Pharma
Ascelia Pharma AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 10 employees.
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.


See the full analysis of Ascelia Pharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card